



Kimia Biosciences Limited

Regd. Office/Works : Village-Bhondsi, Tehsil-Sohna, Distt. Gurugram (Haryana)
E-mail : compliance.kimia@gmail.com & info@kimiabiosciences.com
Web : www.kimiabiosciences.com | CIN NO. : L24239HR1993PLC032120
Tel. : +91 9654746544, 9654206544

November 11, 2021

Ref : KIMIABL/COMP/BSE/21-22/034

To
Department of Corporate Affairs- Listing
BSE Limited
PhirozJeeJeebhoy Towers,
Dalal Street, Fort Mumbai-400001

Scrip Code: 530313 [KIMIABL]
ISIN: INE285U01025

Sub: Outcome of Board Meeting held on Thursday, November 11, 2021

Dear Sir,

Pursuant to Regulation 33 and 47 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board of Directors of the Company in their meeting held today i.e. Thursday, November 11, 2021, has inter-alia considered and approved:


1. Unaudited Financial Results for the second quarter and half year ended September 30, 2021, duly approved and taken on record by the Board of Directors at its meeting held today i.e. Thursday, November 11, 2021.
2. Limited Review Report on the aforesaid results from Statutory Auditors of the Company, as placed before the Board of Directors of the Company in its meeting held today.

The Board Meeting commenced at 02:00 p.m. and concluded at 05:20 p.m.

Kindly take the above information on your records.

Thanking You,
Yours faithfully,

For **KIMIA BIOSCIENCES LIMITED**


Abhishek Kumar Pandey
(Company Secretary & Compliance Officer)



PLACE: New Delhi
Encl.: a/a

Independent Auditor's Review Report on Quarterly and Half Yearly Unaudited Financial Results Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation 2015, as amended

To the Board of Directors of Kimia Biosciences Limited

1. We have reviewed the accompanying statement of unaudited financial results ("the Statement") of Kimia Biosciences Limited ("the Company") for the quarter and half year ended September 30, 2020. This Statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on the statement based on our review.
2. This Statement, which is the responsibility of the Company's management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("IND AS 34"), prescribed under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial results are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results read with notes therein, prepared in all material respects in accordance with the applicable accounting standards and other recognized accounting practices and policies, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Singhi & Co.
Chartered Accountants
Firm Registration No. 302049E




Bimal Kumar Sipani
Partner

Membership No. 088926
UDIN : 21088926AAAAPS1081

Place: Noida (Delhi – NCR)
Date: November 11, 2021

KIMIA BIOSCIENCES LIMITED

Regd. Office : Village Bhondsi, Tehsil Sohna, Dist. Gurgaon , Haryana - 122102

Phone : +91 9654746544, 9654206544 Email: compliance.kimia@gmail.com & info@kimiabiosciences.com

Website: www.kimiabiosciences.com, CIN : L24239HR1993PLC032120

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2021


S. No.	Particulars	Quarter ended			Half Year ended		Year Ended
		30-09-21	30-06-21	30-09-20	30-09-21	30-09-20	31-03-21
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
I	Revenue from Operations	3,092.71	3,086.91	3,750.28	6,179.62	6,235.31	13,271.38
II	Other Income	32.14	17.36	106.01	49.63	143.11	245.62
III	Total Income (III)	3,124.85	3,104.30	3,856.29	6,229.15	6,378.42	13,517.00
IV	Expenses:						
a)	Cost of materials consumed	2,447.13	2,082.20	2,202.25	4,529.33	4,761.67	10,312.59
b)	Change in inventories of finished goods and work-in-progress	(183.50)	50.21	482.10	(133.28)	(429.80)	(627.22)
c)	Employee benefits expenses	368.56	365.20	343.33	733.78	835.24	1,409.10
d)	Finance costs	90.17	78.23	90.98	168.40	163.84	309.00
e)	Depreciation and amortisation expense	75.25	65.21	41.13	141.46	81.54	191.06
f)	Other expenses	496.39	419.35	335.60	915.75	610.50	1,339.03
V	Total Expenses (IV)	3,265.00	3,060.40	3,495.29	6,355.42	5,819.99	12,963.56
VI	Profit/(loss) Before Tax (IV-V)	(170.15)	43.90	360.90	(126.27)	558.43	553.44
VII	Tax expenses:						
a)	Current Tax	-	-	-	-	-	-
b)	Deferred Tax charge / (reversal)	(43.36)	12.12	-	(31.23)	-	43.00
VIII	Profit/(loss) for the period (VI-VII)	(126.79)	31.78	360.90	(95.04)	558.43	510.44
IX	Other Comprehensive Income						
A.	Items that will not be reclassified to Profit or Loss (Net of Tax)						
-	Remeasurement of defined benefit plans	-	-	-	-	-	(3.99)
B.	Items that will be reclassified to Profit or Loss (Net of Tax)						
X	Total Comprehensive Income for the period (VIII+IX)	(126.79)	31.78	360.90	(95.04)	558.43	506.45
XI	Paid up equity share capital (Face value of Rs.1 per equity share)	473.13	473.13	473.13	473.13	473.13	473.13
XII	Other Equity						1,379.52
XIII	Earnings per equity share (not annualised)						
	Basic in Rs.	(0.27)	0.07	0.75	(0.20)	1.18	1.09
	Diluted in Rs.	(0.27)	0.07	0.75	(0.20)	1.18	1.08

STATEMENT OF ASSETS, EQUITY and LIABILITIES

S. No.	Particulars	As at 30-09-2021 (Unaudited)	As at 31-03-2021 (Audited)
A	ASSETS		
1	Non-Current Assets		
	Property, Plant & Equipment	3405.78	2827.25
	Capital Work-in-Progress	75.33	577.01
	Right of Use Assets	0.00	0.00
	Other Intangible Assets	15.27	9.52
	Financial Assets		
	(i) Other Non Current Financial Assets	17.28	17.28
	Other Non-current Assets	30.12	51.70
2	Current Assets		
	Inventories	2641.68	2368.72
	Financial Assets		
	(i) Investment	6.06	5.84
	(ii) Trade Receivables	3064.91	4176.57
	(iii) Cash and Cash Equivalents	21.50	58.89
	(iv) Bank balances other than (iii) above	59.51	106.73
	(v) Other Current Financial Assets	50.88	53.21
	Current Tax Assets (Net)	71.56	70.12
	Other Current Assets	307.25	172.09
	Non-Current Assets Classified as Held for Sale	170.20	170.20
	Total Assets	9977.33	10668.93
B	EQUITY & LIABILITIES		
1	EQUITY		
	(a) Share Capital	473.13	473.13
	(b) Other Equity	1275.48	1376.52
2	NON CURRENT LIABILITIES		
	Financial Liabilities		
	(i) Borrowings	2711.01	2834.63
	(ii) Other Financial Liabilities	468.09	448.41
	Deferred Tax Liabilities (Net)	12.58	43.80
	Provisions	133.33	116.94
	Other Non-Current Liabilities	259.70	264.66
3	CURRENT LIABILITIES		
	Financial Liabilities		
	(i) Borrowings	1687.76	1658.36
	(ii) Trade Payables		
	a. Total Outstanding due to Micro and Small Enterprises	29.32	21.10
	b. Total Outstanding due to other than Micro and Small Enterprises	2558.69	3057.53
	(iii) Other Financial Liabilities	259.94	262.54
	Provisions	5.29	5.29
	Other Current Liabilities	105.55	89.99
	Total Equity and Liabilities	9977.33	10668.93


James J...

STATEMENT OF CASH FLOWS

Particulars	For the year ended: September 30, 2021 (Unaudited)	For the year ended: September 30, 2020 (Unaudited)
A. Cash Flow from Operating Activities		
Net Profit before tax	(124.27)	558.43
Adjustment for:		
Depreciation and amortization expense	141.46	81.54
Loss / (profit) on sale/disposal of property, plant and equipment (net)	-	-
Finance costs	168.40	160.84
Gain on fair value of investment in mutual funds	(0.22)	(2.35)
Interest income	(0.80)	(0.57)
Deferred revenue income	(24.95)	(64.15)
Unrealised (gain)/loss on foreign currency transactions and translations	(0.03)	49.86
Operating Profit Before Working Capital Changes	157.99	783.60
Adjustments for:		
(Increase) / Decrease in inventories	(272.96)	(485.12)
(Increase) / Decrease in trade and other receivables	978.82	(831.84)
Increase / (Decrease) in trade and other payables	(483.50)	315.42
Cash Generated From Operations	379.95	(218.94)
Less : Income tax paid (refunds)	(1.44)	5.23
Net Cash From Operating Activities	378.51	(212.71)
B. Cash Flow from Investment Activities		
Purchases of property, plant and equipments including intangible assets & capital advances	(109.57)	(505.74)
Proceeds from sales of property, plant & equipment	16.31	-
Net inflow / (outflow) in fixed deposits	9.23	19.68
Purchase of current investments	-	(30.00)
Interest received	0.80	0.57
Net Cash Used in Investing Activities	(173.23)	(515.51)
C. Cash Flow from Financing Activities		
Receipts from non current borrowings	428.41	744.60
Repayment of non current borrowings	(574.47)	(306.31)
Net proceeds of current borrowings	51.84	483.22
Finance costs paid	(148.22)	(101.42)
Net Cash Used in Financing Activities	(242.44)	739.89
Net Increase(Decrease) in Cash and Cash Equivalents	(37.16)	1.87
Cash and Cash Equivalents at the beginning of the period	58.66	23.18
Cash and Cash Equivalents at the end of the period	21.50	25.05

Other Notes

- The business activity of the Company falls within a single primary business segment viz 'Pharmaceuticals' and hence there is no other reportable segment as per Ind AS 108 'operating segments'.
- COVID - 19 pandemic has caused disruption on the global economic and business environment. There is uncertainty with regard to its impact which cannot be reasonably determined at this stage. However, the Company has evaluated and considered to the extent possible the likely impact that may arise from COVID-19 pandemic as well as all event and circumstances upto the date of approval of these financial results on the carrying value of its assets and liabilities as at September 30, 2021. Based on the current indicators of future economic conditions, the Company estimates to recover the carrying amount of its assets and has adequate liquidity to discharge its obligations. These estimates are subject to uncertainty and may be affected by the severity and duration of the pandemic. The Company is continuously monitoring any material changes in future economic conditions.
- The figures for the previous periods have been regrouped/ rearranged, wherever considered necessary, to confirm current period classifications.
- The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 11.11.2021

Date : November 11, 2021
 Place : New Delhi



FOR KIMIA BIOSCIENCES LIMITED

(Signature)
 Sameer Goel
 (Managing Director)
 DIN - 00161785